{
  "$schema": "folio-library-entry/v1",
  "id": "10665-385385",
  "blocks": [
    {
      "id": "library/10665-385385/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 9,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Global\nhepatitis\nreport\n2026\nGlobal\nhepatitis\nreport\n2026\nGlobal hepatitis report 2026\nISBN 978-92-4-012238-3 (electronic version)\nISBN 978-92-4-012239-0 (print version)\n© World Health Organization 2026\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO \nlicence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the \nwork is appropriately cited, as indicated below. In any use of this wo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO's Global hepatitis report 2026, with the cover, ISBN and copyright page, licence terms and suggested citation. The table of contents lists chapters on global commitments and targets, epidemic status and trends, prevention, diagnosis and treatment, and the road to elimination, plus annexes on methods, reporting and Health Assembly resolutions. Short statements from the WHO Director-General and the Director of the Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections say progress is real but too slow and uneven to reach the 2030 elimination targets and call for faster, integrated action.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p006-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../images/img-p006-1.webp",
      "narrative": "draft",
      "content": "Head-and-shoulders portrait photograph of Dr Tedros Adhanom Ghebreyesus, WHO Director-General, who signs the foreword on this page.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p007-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../images/img-p007-1.webp",
      "narrative": "draft",
      "content": "Head-and-shoulders portrait photograph of Dr Tereza Kasaeva, Director, Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, who signs the foreword on this page.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 9,
      "pageEnd": 12,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "from Katherine Floyd. Irwin Law coordinated the preparation of all graphics and tables. \nWithin WHO, the report team is grateful to various \npeople for their inputs to and advice on report content. \nParticular thanks are due to Carolina Danovaro, Laure \nDumolard, Marta Gacic-Dobo and Stephanie Shendale \nfrom the Department of Immunization, Vaccines and \nBiologicals for their review of content related to hepatitis B vaccination; and to Wahyu Retno (Annet) Mahanani \nand Bochen Cao (Department for Data, Analytics, Digital \nHealth and Artificial Intelligence) for their review of Chapter 3 and asso",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The acknowledgements of the Global hepatitis report 2026 name the core team in the WHO Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, those who prepared each chapter and annex, and the staff who designed the data collection form and managed data and code. They also thank WHO reviewers, external partners who produced model-based estimates and graphics, the European Centre for Disease Prevention and Control, and the Government of France for funding. Most of the section lists, by WHO region, the regional and country office staff who supported country reporting.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-001-abbreviations.md",
      "narrative": null,
      "content": "ALT\t\nalanine aminotransferase\nBCG\t\nbacille Calmette-Guérin \nCDAF\t\nCenter for Disease Analysis Foundation \nCOVID-19\t coronavirus disease\nDAA\t\ndirect-acting antiviral\nECDC \nEuropean Centre for Disease Prevention and \nControl\nEMTCT\t\nelimination of mother-to-child transmission \nGDP\t\ngross domestic product\nGHO\t\nGlobal Health Observatory\nGHSS\t\nGlobal health sector strategy\nHAV\t\nhepatitis A virus\nHBIG\t\nhepatitis B immunoglobulin\nHBsAg\t\nhepatitis B surface antigen\nHBcAg\t\nhepatitis B core antigen\nHBeAg \t\nhepatitis B e antigen\nHBV\t\nhepatitis B virus\nHCC\t\nhepatocellular carcinoma \nHCV\t\nhepatitis C virus",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The list of abbreviations used in the Global hepatitis report 2026.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 13,
      "pageEnd": 19,
      "target": "../sections/sec-002-1-introduction.md",
      "narrative": null,
      "content": "Viral hepatitis is one of the world’s most important public \nhealth challenges. Hepatitis B virus (HBV) and hepatitis \nC virus (HCV) continue to cause chronic infection in hundreds of millions of people, leading to cirrhosis, liver cancer and over 1 million premature deaths each year, even \nthough both infections are preventable and treatable. \nTogether, HBV and HCV account for over 95% of global \nmortality caused by viral hepatitis, with hepatitis A virus \n(HAV), hepatitis D virus (HDV) and hepatitis E virus (HEV) \naccounting for the remainder.\nPeople can be infected with viral hepatitis thro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The introduction to the Global hepatitis report 2026 explains that hepatitis B and C cause chronic infection in hundreds of millions of people and over 95% of viral hepatitis deaths, and outlines how the five hepatitis viruses are transmitted. It recalls the commitment of all Member States to eliminate viral hepatitis as a public health threat by 2030 and the five interventions that can achieve it, from hepatitis B vaccination to testing and treatment, alongside research on a hepatitis B cure and a hepatitis C vaccine. It describes the report as the fourth global assessment since reporting began in 2016, covering 2015–2024 and drawing on data from 140 reporting Member States and model-based estimates, and sets out the chapter structure. Box 1.1 gives basic facts on each hepatitis virus, and the section ends with an overview of the latest status against the 2030 impact and service coverage targets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Global commitments, strategies and targets",
      "pageStart": 19,
      "pageEnd": 23,
      "target": "../sections/sec-003-2-global-commitments-strategies-and-targets.md",
      "narrative": null,
      "content": "and targets \nfor countries to develop national strategies, expand \nvaccination coverage (including a timely birth dose), \nstrengthen infection control, provide comprehensive services for people who inject drugs (e.g. needle and syringe \nprogrammes and opioid agonist therapy) and ensure \nequitable access to affordable diagnostics and medicines. \nPolitical commitment to combating viral hepatitis entered a new phase in 2015, when the UN General \nAssembly adopted the 2030 Agenda for Sustainable \nDevelopment. The Sustainable Development Goals \n(SDGs) included hepatitis within SDG target 3.3, which",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Traces how viral hepatitis rose onto the global health agenda, from a 1975 Health Assembly resolution on blood safety and the 1992 call to add hepatitis B vaccine to infant schedules, through the 2010 and 2014 resolutions, World Hepatitis Day, the Global Hepatitis Programme and the 2015 SDG target 3.3. It describes WHO's first Global health sector strategy on viral hepatitis (2016–2021), which set the goal of elimination by 2030 with a 90% cut in new infections and a 65% cut in deaths from 2015 levels, five intervention areas, a two-phase expansion and a diagnosis and treatment cascade. The section ends with a table of the current 2030 impact and service coverage targets and the latest status of progress against them.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2.1. The global strategy on viral hepatitis, 2022–2030: vision, goal, indicators and elimination targets for 2030",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../tables/table-2-1.csv",
      "narrative": "draft",
      "content": "Summary of the global health sector strategy on viral hepatitis 2022–2030: its vision and goal, followed by indicators and their 2030 elimination targets, grouped into epidemic impact (incidence, prevalence, mortality) and service coverage (vaccination, diagnosis, treatment, harm reduction, blood and injection safety).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Epidemic status and trends",
      "pageStart": 23,
      "pageEnd": 49,
      "target": "../sections/sec-004-3-epidemic-status-and-trends.md",
      "narrative": null,
      "content": "There are five hepatitis viruses: A, B, C, D and E (HAV, \nHBV, HCV, HDV and HEV). This chapter focuses on HBV \nand HCV, because they account for more than 95% of viral \nhepatitis-related deaths (Chapter  1) and are the forms \nof hepatitis for which global targets have been set in the \nWorld Health Organization (WHO) Global health sector \nstrategy on viral hepatitis, 2022–2030 (GHSS 2022–2030) \n(Chapter 2). \nPeople can be infected with HBV and HCV through \nexposure to infected blood (HBV and HCV) or other bodily \nfluids (HBV). In highly endemic areas, most chronic HBV \ninfections occur in child",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on the status and trends of the viral hepatitis epidemic, which concentrates on hepatitis B and C because they cause over 95% of hepatitis deaths, explaining how each virus is transmitted, how infection progresses silently over decades to cirrhosis and liver cancer, and how incidence, prevalence and mortality are defined. Reviews the available interventions (hepatitis B vaccination, antiviral treatment and prophylaxis, a 12-week direct-acting antiviral cure for hepatitis C, blood safety, infection control and harm reduction) and the 2030 elimination targets. Its key findings put 2024 deaths at about 1.1 million from HBV and 240 000 from HCV, with HBV deaths up 17% since 2015 and concentrated in the African and Western Pacific regions, HCV deaths down 12%, and an estimated 240 million people living with chronic HBV and 47 million with HCV infection. Closes with a section on hepatitis D, which weighs most on low- and middle-income countries with limited testing, and a table comparing the latest coverage indicators with their 2030 targets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p026",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../figures/vfig-p026.webp",
      "narrative": "draft",
      "content": "Part of Figure 3.1: four line charts with shaded uncertainty bands for 2015–2024, HBV in blue (top) and HCV in green (bottom). The right-hand panels show incidence as number per 100 000 population per year (axis 0–30); the HBV rate falls from about 18 to about 11, while the HCV rate declines slightly from about 13 to about 11. The left-hand panels (absolute numbers) are shown with their axis labels cropped off.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p027",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../figures/vfig-p027.webp",
      "narrative": "draft",
      "content": "Part of Figure 3.2: six blue line charts with shaded uncertainty bands showing trends in new HBV infections by WHO region; the lower row is labelled European Region, Eastern Mediterranean Region and Western Pacific Region, while the upper-row titles and some axis labels are cropped. All panels show declining incidence, most steeply in the European and Western Pacific regions (Western Pacific falling from about 0.17 to about 0.09 on its axis).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p028",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../figures/vfig-p028.webp",
      "narrative": "draft",
      "content": "Part of Figure 3.3: six green line charts with shaded uncertainty bands showing trends in new HCV infections by WHO region; the lower row is labelled European Region, Eastern Mediterranean Region and Western Pacific Region, while the upper-row titles are cropped. Most panels show flat or gently declining lines; the upper-middle panel is the exception, rising from about 0.12 to about 0.18 on its axis.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p029-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../images/img-p029-1.webp",
      "narrative": "draft",
      "content": "World map of HCV incidence rates (new infections per 100 000 population) at country level, 2024 (Fig. 3.5), with countries shaded in greens from light (<2) to dark (≥20). The darkest shades appear in scattered countries, including the United States of America, Pakistan and several countries in Africa and Central Asia, while much of Latin America, China and Australia are in the lightest shade.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p029-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../images/img-p029-3.webp",
      "narrative": "draft",
      "content": "World map of HBV incidence rates (new infections per 100 000 population) at country level, 2024 (Fig. 3.4), with countries shaded in blues from light (<2) to dark (≥20). The darkest shade covers most of sub-Saharan Africa and a few countries in South-East Asia and the Western Pacific, while the Americas, Europe and Australia are in the lightest shade.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p029",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../figures/vfig-p029.webp",
      "narrative": "draft",
      "content": "Legend fragments of the country maps in Figures 3.4 and 3.5 (number per 100 000 population). The HBV legend uses blue classes <2, 2–10, 11–19 and ≥20; the HCV legend uses green classes <5, 5–12, 13–19 and ≥20; both include No data and Not applicable. The maps themselves are almost entirely cropped out.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.1. Contribution of unsafe medical injections to new HCV infections by WHO region, 2023",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../tables/table-3-1.csv",
      "narrative": "draft",
      "content": "For each WHO region and globally, the table gives the number of studies included and the estimated percentage of new HCV infections attributable to unsafe medical injections in 2023, with 95% uncertainty intervals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.2. HCV incidence among people who inject drugs, globally and by WHO region, pre-2015 and in the period 2015–2021 (47)",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../tables/table-3-2.csv",
      "narrative": "draft",
      "content": "HCV incidence among people who inject drugs, per 100 person-years, by WHO region and globally, comparing the pre-2015 period with 2015–2021, plus the incidence rate ratio between the two periods where it could be estimated.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.3. Prevalence of chronic HBV infection among children aged under 5 years, globally and by WHO region, 2024",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../tables/table-3-3.csv",
      "narrative": "draft",
      "content": "Estimated percentage prevalence of chronic HBV infection among children under 5 years in 2024, for each WHO region and globally, with 95% uncertainty intervals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p031",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../figures/vfig-p031.webp",
      "narrative": "draft",
      "content": "Part of Figure 3.7: six blue line charts with shaded uncertainty bands showing prevalence of chronic HBV infection among children under 5 years by WHO region; the lower row is labelled European Region, Eastern Mediterranean Region and Western Pacific Region, and the upper-row titles are cropped. All regions decline; the steepest fall is in the upper-right panel, from about 0.55 to about 0.25.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p032-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../images/img-p032-3.webp",
      "narrative": "draft",
      "content": "World map of the prevalence of chronic HBV infection among children aged under 5 years at country level, 2024 (Fig. 3.8), shaded in blues for <0.1%, 0.1–0.9% and ≥1%. The darkest shade (≥1%) covers most of sub-Saharan Africa and a few countries in Asia and the Western Pacific, while the Americas, Europe and Australia are in the lightest shade.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p032",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../figures/vfig-p032.webp",
      "narrative": "draft",
      "content": "Lower part of Figure 3.8, a world choropleth map of chronic HBV prevalence among children under 5 years, with legend Prevalence (%): <0.1, 0.1–0.9, ≥1, No data and Not applicable. The darkest shading (≥1%) is visible across much of central and southern Africa and in Papua New Guinea. Below it the title of Table 3.4 and its header row (WHO region, Country) appear.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.4. Countries that had surpassed (in 2024) the 2030 SDG target of reducing the prevalence of chronic HBV infection among children aged under 5 years to 0.1%",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../tables/table-3-4.csv",
      "narrative": "draft",
      "content": "Lists, by WHO region and with the number of countries in each, the countries that by 2024 had already reduced the prevalence of chronic HBV infection among children under 5 to the 2030 SDG target of 0.1% or below.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p033",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../figures/vfig-p033.webp",
      "narrative": "draft",
      "content": "Table 3.5 and Figure 3.9. The table gives, by WHO region, prevalence in the general population (%) and total number of people infected (millions), with 95% uncertainty intervals, for chronic HBV and HCV infection; globally 2.9% (240 million) for chronic HBV and 0.6% (47 million) for HCV, with the Western Pacific (102 million) and African (64 million) regions having the most people with chronic HBV. Figure 3.9 shows two line charts with uncertainty bands, labelled “Millions per year”: chronic HBV (blue) declining slightly from about 260 to about 240 million, and HCV (green) from about 58 to about 47 million.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-006",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.5. Prevalence of HBV and HCV infections, globally and by WHO region, 2024",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../tables/table-3-5.csv",
      "narrative": "draft",
      "content": "For each WHO region and globally in 2024, the table gives the prevalence (%) of chronic HBV infection and of HCV infection in the general population, and the total number of people of all ages infected (millions), each with 95% uncertainty intervals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p034-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../images/img-p034-3.webp",
      "narrative": "draft",
      "content": "World map of the prevalence of chronic HBV infection in the general population at country level, 2024 (Fig. 3.11), shaded in blues for <2%, 2–4.9%, 5–7.9% and ≥8%. The darkest shades appear in several countries of West, Central and East Africa, intermediate shades across much of the rest of Africa and parts of Asia, and the lightest shade across the Americas, Europe and Australia.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p034",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../figures/vfig-p034.webp",
      "narrative": "draft",
      "content": "Figure 3.10 (partly cropped at the top) and Figure 3.11. Figure 3.10 shows six blue line charts, 2015–2024, of the estimated number of people with chronic HBV infection by WHO region (millions; shaded areas are 95% uncertainty intervals); all lines are flat or slowly declining, e.g. Western Pacific from about 115 to about 102 million and European Region from about 11 to about 10 million. Figure 3.11 is a world choropleth map of chronic HBV prevalence in the general population, 2024 (%), with classes <2, 2–4.9, 5–7.9 and ≥8; the highest classes are concentrated in sub-Saharan Africa, with intermediate levels in parts of Asia and the Pacific.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p035",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 35,
      "pageEnd": 35,
      "target": "../figures/vfig-p035.webp",
      "narrative": "draft",
      "content": "Figure 3.12, a treemap in which each rectangle is a country sized by its number of people with chronic HBV infection, coloured by region. China is by far the largest block, followed by India, then Nigeria, Indonesia, Ethiopia, Bangladesh and Viet Nam; other labelled countries include the Philippines, Pakistan, South Africa, Democratic Republic of the Congo, Angola, Mozambique, Sudan, Türkiye, Ghana, Niger, Myanmar, Kenya and Côte d'Ivoire, with many small unlabelled countries.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p036-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../images/img-p036-3.webp",
      "narrative": "draft",
      "content": "World map of the prevalence of HCV infection in the general population at country level, 2024 (Fig. 3.14), shaded in five greens from <0.25% to ≥2%. The darkest shades appear in a few countries in Central and South Asia, Eastern Europe and Central Africa; middle shades cover much of the Americas, Africa and the Russian Federation, while China, India and parts of Western Europe are lighter.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p036",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../figures/vfig-p036.webp",
      "narrative": "draft",
      "content": "Figure 3.13 (upper titles cropped) and Figure 3.14. Figure 3.13 shows six green line charts, 2015–2024, of the estimated number of people with HCV infection by WHO region (millions per year, with 95% uncertainty bands); most decline, e.g. Eastern Mediterranean from about 18 to about 12 million and European Region from about 8 to about 5.6 million. Figure 3.14 is a world choropleth map of HCV prevalence in the general population, 2024 (%), with classes <0.25, 0.25–0.49, 0.5–0.99, 1–1.99 and ≥2; higher prevalence is visible in parts of Africa, Central Asia, Pakistan and eastern Europe.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p037",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 37,
      "pageEnd": 37,
      "target": "../figures/vfig-p037.webp",
      "narrative": "draft",
      "content": "Figure 3.15 and Figure 3.16. Figure 3.15 is a stacked bar chart of millions of people living with HBV (blue) or HCV (green) in 2024 in 20 countries: China is highest (about 74 million in total, mostly HBV), followed by India (about 35 million), Nigeria, Indonesia and Pakistan, where HCV forms the larger share; the remaining countries run from Ethiopia down to Côte d'Ivoire. Figure 3.16 is a treemap of the global number of people with HCV infection by country, coloured by region, in which Pakistan and India are the largest blocks, followed by China, the United States of America, Nigeria, the Russian Federation, Indonesia, Bangladesh and Viet Nam.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p039",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 39,
      "pageEnd": 39,
      "target": "../figures/vfig-p039.webp",
      "narrative": "draft",
      "content": "Figure 3.17 (left panel axis cropped) and Figure 3.18. Figure 3.17 shows global HBV-related mortality with 95% uncertainty bands, both rising slowly; the right panel (number per 100 000 population per year) rises from about 12.7 to about 13.6. Figure 3.18 shows six blue line charts of HBV-related deaths by WHO region (African, Americas, South-East Asia, European, Eastern Mediterranean and Western Pacific); all increase gradually, with the Western Pacific highest (about 470 000 to about 525 000) and South-East Asia rising from about 128 000 to about 162 000.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p040-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 40,
      "pageEnd": 40,
      "target": "../images/img-p040-3.webp",
      "narrative": "draft",
      "content": "World map of HBV-related mortality rates (deaths per 100 000 population) at country level, 2024 (Fig. 3.20), shaded in blues for <4, 4–6.9, 7–9.9 and ≥10. The darkest shade covers most of sub-Saharan Africa, China, Mongolia and much of South-East Asia, while the Americas, Western Europe and Australia are in the lightest shade.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p040",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 40,
      "pageEnd": 40,
      "target": "../figures/vfig-p040.webp",
      "narrative": "draft",
      "content": "Figure 3.19 (upper titles cropped) and Figure 3.20. Figure 3.19 shows six blue line charts, 2015–2024, of HBV-related mortality rates by WHO region (number per 100 000 population per year, with 95% uncertainty bands); rates are roughly flat, highest at about 24 in the upper-left panel and about 22–24 in the Western Pacific, and about 4 in the European Region. Figure 3.20 is a world choropleth map of HBV-related mortality rates per 100 000 population in 2024, with classes <4, 4–6.9, 7–9.9 and ≥10; the highest class covers most of sub-Saharan Africa, China and parts of South-East Asia.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p041",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 41,
      "pageEnd": 41,
      "target": "../figures/vfig-p041.webp",
      "narrative": "draft",
      "content": "Figure 3.21 and Figure 3.22. Figure 3.21 is a treemap of each country’s share of global HBV-related deaths in 2024, coloured by WHO region (African, Americas, Eastern Mediterranean, European, South-East Asia, Western Pacific), with only the top 20 countries labelled; China is by far the largest block, followed by India, Indonesia, Nigeria, Viet Nam, Bangladesh and Ethiopia. Figure 3.22 shows global HCV-related mortality with 95% uncertainty bands: absolute numbers decline from about 0.27 to about 0.24 million per year, and the rate from about 3.6 to about 2.9 per 100 000 population per year.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p042",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 42,
      "pageEnd": 42,
      "target": "../figures/vfig-p042.webp",
      "narrative": "draft",
      "content": "Part of Figure 3.23: six green line charts with shaded uncertainty bands of the absolute number of HCV-related deaths by WHO region, 2015–2024; the lower row is labelled European Region, Eastern Mediterranean Region and Western Pacific Region, and the upper-row titles are cropped. The European and Eastern Mediterranean regions decline (Eastern Mediterranean from about 72 000 to about 48 000), the Western Pacific is roughly flat at about 45 000–50 000, and two upper panels rise.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p043-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 43,
      "pageEnd": 43,
      "target": "../images/img-p043-3.webp",
      "narrative": "draft",
      "content": "World map of HCV-related mortality rates (deaths per 100 000 population) at country level, 2024 (Fig. 3.25), shaded in greens for <2, 2–2.9, 3–4.9 and ≥5. The darkest shades appear in countries including the Russian Federation, Pakistan, Japan, Colombia, Argentina and several countries of southern Africa, while China, Brazil, Australia and much of Africa are in the lightest shade.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p043",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 43,
      "pageEnd": 43,
      "target": "../figures/vfig-p043.webp",
      "narrative": "draft",
      "content": "Figure 3.24 (upper titles cropped) and Figure 3.25. Figure 3.24 shows six green line charts, 2015–2024, of HCV-related mortality rates by WHO region (number per 100 000 population per year, with 95% uncertainty bands); the Eastern Mediterranean falls from about 10 to about 6 and the European Region from about 4.9 to about 3.3, while one upper panel rises slightly from about 1.8 to about 2.1. Figure 3.25 is a world choropleth map of HCV-related mortality rates per 100 000 population in 2024, with classes <2, 2–2.9, 3–4.9 and ≥5; the highest class appears in countries including the Russian Federation, Pakistan, parts of southern Africa and South America.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p044",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../figures/vfig-p044.webp",
      "narrative": "draft",
      "content": "Figure 3.26 and Figure 3.27. Figure 3.26 is a treemap of each country’s share of global HCV-related deaths in 2024, coloured by WHO region, with only the top 20 countries labelled; Pakistan and India are the largest blocks, followed by China, the United States of America, Japan, Indonesia, the Russian Federation, Nigeria and South Africa. Figure 3.27 shows global HBV and HCV-related deaths combined (orange), HBV only (blue) and HCV only (green), 2015–2024, with uncertainty bands: combined deaths rise from about 1.2 to about 1.35 million per year, driven by HBV (about 0.95 to 1.1 million), while HCV stays near 0.25 million; the combined rate stays at about 16 per 100 000 population per year.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p045-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 45,
      "pageEnd": 45,
      "target": "../images/img-p045-1.webp",
      "narrative": "draft",
      "content": "World map of the combined HBV- and HCV-related mortality rate (deaths per 100 000 population) at country level, 2024 (Fig. 3.28), shaded in oranges for <6, 6–9.9, 10–14.9 and ≥15. The darkest shade covers most of sub-Saharan Africa, China and much of South and South-East Asia, while the Americas, Western Europe and Australia are mostly in the lightest shades.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p045",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 45,
      "pageEnd": 45,
      "target": "../figures/vfig-p045.webp",
      "narrative": "draft",
      "content": "Legend fragment of the country map in Figure 3.28 (number per 100 000 population), with orange-to-red classes <6, 6–9.9, 10–14.9 and ≥15, plus No data and Not applicable; the map itself is not included.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Prevention, diagnosis and treatment",
      "pageStart": 49,
      "pageEnd": 73,
      "target": "../sections/sec-005-4-prevention-diagnosis-and-treatment.md",
      "narrative": null,
      "content": "Viral hepatitis remains a leading global health problem \n(Chapter 3). \nGlobally in 2024, the sequelae of chronic hepatitis B \nvirus (HBV) and hepatitis C virus (HCV) infections – liver \ncirrhosis and hepatocellular cancer (HCC) – caused a combined total of 1.3 million deaths (95% uncertainty interval [UI]: 1.1–1.7 million). This included 1.1 million (95% UI: \n0.9–1.3 million) HBV-related deaths and 240 000 (95% UI: \n160 000–370 000) HCV-related deaths. \nGlobally in 2024, there were an estimated 240 million \npeople living with a chronic HBV infection (95% UI: 202–\n296 million), equivalent to 2.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the latest coverage data for hepatitis prevention, diagnosis and treatment, recalling that HBV and HCV caused 1.3 million deaths and 1.8 million new infections in 2024 and setting out the coverage levels the global health sector strategy requires by 2025 and 2030. Covers the most impactful interventions first: hepatitis B birth-dose and infant vaccination (with 118 of 194 Member States providing universal birth-dose vaccination as of December 2025), antiviral prophylaxis against mother-to-child transmission, and antiviral treatment for chronic HBV and HCV infection. Later sections address blood and injection safety in health care and harm-reduction services for people who inject drugs, who account for about 44% of new HCV infections. Concludes that harm-reduction coverage is far below recommended levels, with about 35 needles and syringes distributed per person who injects drugs each year against a 2030 target of 300, only 18 in 100 having access to OAMT, and only five countries reaching high coverage of both services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/table-007",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.1. Global status of progress (in 2024) towards intervention coverage targets for elimination set in WHO’s global health sector strategy (GHSS) on viral hepatitis, 2022–2030",
      "pageStart": 51,
      "pageEnd": 51,
      "target": "../tables/table-4-1.csv",
      "narrative": "draft",
      "content": "Global status in 2024 of the GHSS viral hepatitis intervention coverage indicators, set against their 2025 and 2030 targets, grouped into hepatitis B vaccination, hepatitis B and C diagnosis and treatment, safety of blood and health-care injections, and harm-reduction services.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p052-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 52,
      "pageEnd": 52,
      "target": "../images/img-p052-1.webp",
      "narrative": "draft",
      "content": "World map of the implementation status of hepatitis B birth-dose vaccination at country level, 2025 (Fig. 4.1), with countries coloured by category (throughout the country, in certain regions, only in risk groups, planned, not administered). Most countries share one colour (blue-grey); many countries in sub-Saharan Africa form a second group (orange); Western European countries, Japan, South Africa and New Zealand a third (green); Canada and Pakistan are pink and a few African countries yellow. The colour key is not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p052",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 52,
      "pageEnd": 52,
      "target": "../figures/vfig-p052.webp",
      "narrative": "draft",
      "content": "Legend fragment of the map in Figure 4.1 on hepatitis B birth-dose vaccination, with categories: Yes, throughout the country (text cropped); Yes, in certain regions; Yes, only in risk groups; Planned; Not administered; No data; and Not applicable. The map itself is not included.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p053",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 53,
      "pageEnd": 53,
      "target": "../figures/vfig-p053.webp",
      "narrative": "draft",
      "content": "Part of Figure 4.3: six blue line charts of timely birth-dose hepatitis B vaccination coverage by WHO region, 2000–2024; the lower row is labelled European Region, Eastern Mediterranean Region and Western Pacific Region, while the upper-row titles and all axis values are cropped or missing. All regions show increases over time; the Western Pacific rises sharply early on and stays highest, and one upper panel stays low with a gradual rise.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p054-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 54,
      "pageEnd": 54,
      "target": "../images/img-p054-3.webp",
      "narrative": "draft",
      "content": "World map of coverage of third-dose hepatitis B vaccination at country level, 2024 (Fig. 4.6), with countries shaded mainly in blue or coral red and one country in dark red. Coral red covers much of Latin America, sub-Saharan Africa, Canada and parts of Europe and South-East Asia, while blue covers countries including the United States of America, Brazil, the Russian Federation, China, India and Australia. The colour key is not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p054",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 54,
      "pageEnd": 54,
      "target": "../figures/vfig-p054.webp",
      "narrative": "draft",
      "content": "Figure 4.5 (upper titles cropped) and Figure 4.6. Figure 4.5 shows six blue line charts of third-dose hepatitis B vaccination coverage (%) by WHO region, 2000–2024; coverage rises in all regions, reaching about 90% in the European and Western Pacific regions and about 75–94% elsewhere, from starting points as low as about 3–5% in two upper panels. Figure 4.6 is a world map of third-dose coverage in 2024 with classes <90%, ≥90%, No universal hepatitis B infant immunization, No data and Not applicable; coverage below 90% is widespread across Africa, Latin America, parts of Europe and South-East Asia.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p056",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 56,
      "pageEnd": 56,
      "target": "../figures/vfig-p056.webp",
      "narrative": "draft",
      "content": "Figure 4.7: stacked horizontal bar charts of the number of countries with national policies on hepatitis B vaccination of adults (Yes, No, Unknown) for eight groups: A health care workers, B people living with HIV, C people who inject drugs, D men who have sex with men, E military personnel, F commercial sex workers, G people with HCV infection and H travellers. Globally (top panel), the “Yes” count is highest for health care workers (107) and lowest for travellers (26), with 73, 65, 60, 45, 43 and 43 for the groups in between. Regional panels for the African, Americas, South-East Asia, European, Eastern Mediterranean and Western Pacific regions follow the same pattern, with health care workers most often covered.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p057-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 57,
      "pageEnd": 57,
      "target": "../images/img-p057-1.webp",
      "narrative": "draft",
      "content": "World map showing whether a national plan exists for the elimination of mother-to-child transmission of HBV as part of triple elimination of HBV, HIV and syphilis, by country, 2025 (Fig. 4.8). Countries are coloured blue or orange, with many others left white and a few in grey; blue covers much of Africa, South America and South-East Asia, while orange includes the Russian Federation, Mexico, Australia and Pakistan. The colour key is not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p057",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 57,
      "pageEnd": 57,
      "target": "../figures/vfig-p057.webp",
      "narrative": "draft",
      "content": "Legend fragment of the map in Figure 4.8, with categories Plan exists, Plan does not exist (text cropped), No data and Not applicable; the map itself is not included.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p058",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 58,
      "pageEnd": 58,
      "target": "../figures/vfig-p058.webp",
      "narrative": "draft",
      "content": "Figure 4.9: stacked horizontal bar charts of the number of countries with policies to prevent mother-to-child transmission (Yes, No, Unknown) for five measures: A screening of all pregnant women for HBV (HBsAg testing), B provision of antiviral prophylaxis during pregnancy, C HBV immunoglobulin recommended to all HBV-exposed infants, D HBeAg or HBV DNA testing among all HBsAg-positive pregnant women, and E HCV screening among pregnant women. Globally, “Yes” counts fall from 128 (A) to 102, 87, 64 and 56 (E). Regional panels for the African, Americas, South-East Asia, European, Eastern Mediterranean and Western Pacific regions mostly show HBV screening of pregnant women as the most common policy.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p059-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 59,
      "pageEnd": 59,
      "target": "../images/img-p059-1.webp",
      "narrative": "draft",
      "content": "World map of the status of implementation of a policy on testing women for HBV infection during pregnancy in public antenatal clinics, by country, 2025 (Fig. 4.10), with categories from implemented in >95% of clinics to policy not in place. Countries are shaded from dark green to pale yellow: many, including Canada, Brazil, the Russian Federation and Indonesia, are dark green, while Australia and some countries in Africa and South Asia are pale yellow; many countries are left white. The colour key is not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p059",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 59,
      "pageEnd": 59,
      "target": "../figures/vfig-p059.webp",
      "narrative": "draft",
      "content": "Legend fragment of the map in Figure 4.10, with green categories Implemented in >95% of clinics, Implemented in 50–95% of clinics, Implemented in <50% of clinics, plus Policy not in place, No data and Not applicable; the map itself is not included.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p061-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 61,
      "pageEnd": 61,
      "target": "../images/img-p061-1.webp",
      "narrative": "draft",
      "content": "Photograph of a health worker in a headscarf talking with a woman wearing a face veil across a desk in a clinic; a sign on the wall reads \"From the People of Japan\". It illustrates Box 4.3 on integrating hepatitis C screening into antenatal care in Cox's Bazar, Bangladesh.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p061-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 61,
      "pageEnd": 61,
      "target": "../images/img-p061-2.webp",
      "narrative": "draft",
      "content": "Photograph of a health worker in a blue uniform consulting a veiled woman who holds an infant at a clinic desk, with health posters on the wall behind. It illustrates Box 4.3 on hepatitis C screening in antenatal care in Cox's Bazar, Bangladesh.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p062",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 62,
      "pageEnd": 62,
      "target": "../figures/vfig-p062.webp",
      "narrative": "draft",
      "content": "Header row of Table 4.2 (coverage of HBV diagnosis and treatment by WHO region, 2024), with columns: WHO region; number of people with a chronic HBV infection in 2024 (millions, 95% UI); number who had been diagnosed by the end of 2024 (millions); number on treatment for HBV by the end of 2024 (millions); percentage diagnosed; percentage of those diagnosed who were on treatment; and percentage of all people with chronic HBV on treatment. No data rows are included.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-008",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.2. Coverage of HBV diagnosis and treatment, globally and by WHO region, 2024",
      "pageStart": 62,
      "pageEnd": 62,
      "target": "../tables/table-4-2.csv",
      "narrative": "draft",
      "content": "HBV cascade of care in 2024 by WHO region and globally: number of people with chronic HBV infection, number diagnosed and number on treatment (millions), and the percentages diagnosed, on treatment among those diagnosed, and on treatment among all infected, each with 95% uncertainty intervals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p064-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 64,
      "pageEnd": 64,
      "target": "../images/img-p064-1.webp",
      "narrative": "draft",
      "content": "World map of national policies on HDV testing among patients diagnosed with HBV infection, 2025 (Fig. B4.4.1 in Box 4.4), with categories: test done for all people with HBV infection, test done in specific groups, testing not done, no data. Countries are coloured green (including Canada, the Russian Federation, Kazakhstan and several European countries), light blue (much of Latin America, Africa and the Middle East) or red (including Australia, Pakistan and several countries in Africa and South-East Asia); many countries are white. The colour key is not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p065-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 65,
      "pageEnd": 65,
      "target": "../images/img-p065-1.webp",
      "narrative": "draft",
      "content": "World map of the status of national HBV treatment guidelines, 2025 (Fig. 4.14), with categories: national guidelines, WHO 2024 HBV guidelines, European Association for the Study of the Liver (EASL) guidelines, no national guidelines. Most reporting countries are light blue; a few are darker blue, several European countries and Gabon are red, and a few countries (e.g. Somalia, Portugal) are yellow, while many countries are white. The colour key is not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p065",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 65,
      "pageEnd": 65,
      "target": "../figures/vfig-p065.webp",
      "narrative": "draft",
      "content": "Lower part of Figure 4.14, a world map of the status of national HBV treatment guidelines, with legend WHO 2024 HBV guidelines, European Association for the Study of the Liver (EASL) guidelines, No national guidelines, No data and Not applicable (the national-guidelines category is cropped); most visible countries are shaded light blue. Below it is the header row of Table 4.3 (coverage of HCV diagnosis and treatment by WHO region, 2024), with columns for cumulative numbers of people with HCV infection, diagnosed and treated in 2015–2024, the corresponding percentages, and the number diagnosed and alive in 2024 but not yet treated.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-009",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.3. Coverage of HCV diagnosis and treatment, globally and by WHO region, 2024",
      "pageStart": 65,
      "pageEnd": 65,
      "target": "../tables/table-4-3.csv",
      "narrative": "draft",
      "content": "HCV diagnosis and treatment coverage by WHO region and globally: cumulative numbers of people with HCV infection, diagnosed and treated at any time in 2015–2024 (millions), the corresponding percentages diagnosed and treated, and the number diagnosed, alive in 2024 and not yet treated, each with 95% uncertainty intervals.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-img-p069-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 69,
      "pageEnd": 69,
      "target": "../images/img-p069-1.webp",
      "narrative": "draft",
      "content": "World map of the status of national HCV treatment guidelines, 2025 (Fig. 4.21), with categories: national guidelines, WHO 2022 HCV guidelines, EASL guidelines, no national guidelines. Most reporting countries are teal; a few are light green, a few (including the United Kingdom, Oman, Gabon and Sri Lanka) are red and a few (e.g. Somalia) are yellow, while many countries are white. The colour key is not part of the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p069",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 69,
      "pageEnd": 69,
      "target": "../figures/vfig-p069.webp",
      "narrative": "draft",
      "content": "Lower part of Figure 4.21, a world map of national HCV treatment guidelines, with legend National guidelines, WHO 2022 HCV guidelines, European Association for the Study of the Liver (EASL) guidelines, No national guidelines, No data and Not applicable; most visible countries have national guidelines. Below it is Box 4.5, “Country examples of hepatitis C services: Ghana and Italy”, a two-column text box describing Ghana’s scale-up of hepatitis C services through the STOP Hep C Ghana initiative and Italy’s screening-driven HCV elimination strategy.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/table-010",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.4. Proportions of blood donations with positive/reactive results on screening tests, by country income group",
      "pageStart": 70,
      "pageEnd": 70,
      "target": "../tables/table-4-4.csv",
      "narrative": "draft",
      "content": "Median and interquartile range of the percentage of blood donations testing positive or reactive for HIV, HBV, HCV and syphilis, by World Bank country income group (high, upper-middle, lower-middle and low income).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p073",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 73,
      "pageEnd": 73,
      "target": "../figures/vfig-p073.webp",
      "narrative": "draft",
      "content": "Part of Figure 5.1: two line charts, 2015–2024, comparing estimates (solid lines with shaded uncertainty bands) with dashed trajectories required to reach the 2030 elimination targets. In the left panel (new chronic HBV infections; axis values cropped) the solid line declines but stays above the steeper dashed trajectory. In the right panel (HBV-related deaths, millions) the solid line rises from about 0.95 to about 1.1 million while the dashed trajectory falls towards about 0.3 million.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The road to elimination",
      "pageStart": 73,
      "pageEnd": 83,
      "target": "../sections/sec-006-5-the-road-to-elimination.md",
      "narrative": null,
      "content": "The possibility that viral hepatitis could be eliminated \nas a public health threat worldwide was first recognized \nby all Member States of the World Health Organization \n(WHO) in 2014 (Chapter 2). Subsequently, the goal of the \nfirst WHO global health sector strategy on viral hepatitis (GHSS 2016–2021) (4), adopted by all Member States \nin 2016, was defined as elimination of viral hepatitis as a \npublic health threat by 2030. This goal was retained in the \nsecond GHSS, for 2022–2030 (3).\nThe 2030 elimination targets are: \n\t\nf a 95% reduction in the annual number of new hepatitis \nB virus (HBV",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Traces the goal of eliminating viral hepatitis as a public health threat by 2030 from its recognition by WHO Member States in 2014 through the two global health sector strategies, and notes that the targets can be met with existing vaccines and antivirals whose prices have fallen sharply since 2015. Finds progress between 2015 and 2024 too slow: new HBV infections fell by 32% and new HCV infections by 8.1%, HBV-related deaths rose by 17% while HCV-related deaths fell by 12%, and in 2024 birth-dose coverage was 45%, under 5% of people with HBV were on treatment and HCV treatment coverage was 20%. Sets out five priorities for global and regional action: scaling up HBV treatment, especially in the African and Western Pacific regions, and HCV treatment, especially in the Eastern Mediterranean Region; raising birth-dose vaccination and antiviral prophylaxis coverage, especially in Africa; and making nonmedical injections safer through harm reduction. Gives 10 country examples, ending with Thailand's free nationwide HCV test-and-treat campaign, which in three years reached 7.3 million people, found almost 75 000 infections and treated more than 50 000.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p074",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 74,
      "pageEnd": 74,
      "target": "../figures/vfig-p074.webp",
      "narrative": "draft",
      "content": "Part of Figure 5.2: two green line charts, 2015–2024, comparing estimates (solid lines with shaded uncertainty bands) with dashed trajectories required to reach the 2030 elimination targets. In the left panel (new HCV infections; axis values cropped) the solid line is nearly flat while the dashed trajectory falls steeply. In the right panel (HCV-related deaths, millions) the solid line declines from about 0.27 to about 0.24 million, staying above the dashed trajectory, which falls to about 0.1 million.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/figure-vfig-p076",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 76,
      "pageEnd": 76,
      "target": "../figures/vfig-p076.webp",
      "narrative": "draft",
      "content": "Cropped legend strip from Figure 5.5 (funding required for HBV and HCV diagnosis and treatment), showing colour keys for “HBV laboratory tests” (blue) and “HCV treatment” (dark green), plus a red key whose label is cut off.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 83,
      "pageEnd": 89,
      "target": "../sections/sec-007-references.md",
      "narrative": null,
      "content": "1.\t\nResolution WHA63.18. Viral hepatitis. In: Sixty-third World Health Assembly, Geneva, 17–21 May 2010. \nResolutions and decisions, annexes. Geneva: World Health Organization; 2010 \n(http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-en.pdf). Licence: CC BY-NC-SA 3.0 IGO.\n2.\t\nResolution WHA67.6. Hepatitis. In: Sixty-seventh World Health Assembly, Geneva, 19–24 May 2014. Resolutions \nand decisions, annexes. Geneva: World Health Organization; 2014 \n(http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf). Licence: CC BY-NC-SA 3.0 IGO.\n3.\t\nGlobal health sector strategies on, respec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the main chapters of the Global hepatitis report 2026, citing World Health Assembly resolutions, WHO strategies and guidelines, and scientific articles.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methodological notes",
      "pageStart": 89,
      "pageEnd": 91,
      "target": "../sections/sec-008-annex-1-methodological-notes.md",
      "narrative": null,
      "content": "This annex summarizes the main updates to methods \nused to produce epidemiological estimates (incidence, \nprevalence and mortality) and associated estimates of \ndiagnostic and treatment coverage, compared with those \nused in previous World Health Organization (WHO) global \nreports on hepatitis, published in 2017 and 2024 (1, 2). The \nupdates reflect the availability of new data, refinements \nin modelling methods and enhanced calibration procedures that, overall, improve the accuracy, comparability \nand interpretability of global and regional trends. \nThe annex also highlights specific methodol",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes how the methods behind the report's estimates of hepatitis incidence, prevalence, mortality and diagnosis and treatment coverage have changed since the 2017 and 2024 reports, chiefly a full recalibration of the HBV and HCV models with the Center for Disease Analysis Foundation that revises past figures, so earlier estimates should not be compared with these. Notes, for example, that HBV prevalence among children under five in 2020 is now put at 0.65% rather than 0.9%, that the 2015 baseline of 6–10 million new infections has been revised downwards, and that time series for 2015–2024 are now provided. Explains that country maps and target assessments rely on modelled estimates, which should prompt national review rather than serve as official proof of elimination, describes how the HBV and HCV cascades of care are presented, and announces updated online country profiles.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The global hepatitis reporting process",
      "pageStart": 91,
      "pageEnd": 93,
      "target": "../sections/sec-009-annex-2-the-global-hepatitis-reporting-process.md",
      "narrative": null,
      "content": "f Regionally validated data. If WHO regional offices had \nalready conducted validation exercises, countries were \nadvised to use those datasets.\n\t\nf WHO estimates. Where there were data gaps, countries were encouraged to use WHO estimates from \n2024, provided they endorsed the figures. If discrepancies existed between national data and WHO estimates, countries were asked to provide explanatory \ncomments.\nFollowing reporting of data, WHO regional and country \noffices supported data validation efforts in collaboration \nwith ministries of health. Upon request, WHO facilitated country-level triang",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes WHO's global hepatitis reporting, held every two years, which in 2025 gathered data for 2024 on the hepatitis B and C burden and on intervention coverage, plus the status of national policies, between July and December. Outlines its phases: a data collection form in four languages, nominated national focal points with access to an online platform launched on 25 June 2025 and backed by webinars, a priority order of validated country data, regionally validated data and WHO estimates, validation support, and a country review of the final datasets in November. A table shows that 140 of the 194 Member States reported data, with participation varying by WHO region.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385385/blocks/table-011",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A2.1. Number of Member States that reported data in the 2025 round of global hepatitis reporting, globally and by WHO region",
      "pageStart": 91,
      "pageEnd": 91,
      "target": "../tables/table-a2-1.csv",
      "narrative": "draft",
      "content": "For each WHO region and all regions combined, the number of Member States and the number that reported data in the 2025 round of global hepatitis reporting.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385385/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "World Health Assembly resolutions on viral hepatitis",
      "pageStart": 93,
      "pageEnd": 96,
      "target": "../sections/sec-010-annex-3-world-health-assembly-resolutions-on-vir.md",
      "narrative": null,
      "content": "on viral hepatitis\nThere have been two World Health Assembly resolutions \non viral hepatitis. The first was adopted in 2010 (WHA63.18) \n(1). The second was adopted in 2014 (WHA67.6) (2). The \nBox A3.1.\t The first World Health Assembly resolution on viral hepatitis in 2010 \n\t\n(WHA63.18): summary of Member State commitments and requests \n\t\nto WHO (1) \nMember State commitments\n\t\nf World Hepatitis Day. Designate 28 July as World \nHepatitis Day, to raise awareness and strengthen \nprevention and control measures.\n\t\nf Surveillance. Implement or improve \nepidemiological surveillance systems, to genera",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the two World Health Assembly resolutions on viral hepatitis, WHA63.18 of 2010 and WHA67.6 of 2014, listing what each committed Member States to and asked of WHO. The 2010 resolution designated 28 July as World Hepatitis Day and called for better surveillance, integrated prevention and care, protection of health workers, access to medicines including through TRIPS flexibilities, and WHO support on goals, research, burden estimates and resource mobilization. The 2014 resolution called on Member States for national multisectoral strategies, stronger immunization including a timely hepatitis B birth dose, civil society involvement, surveillance, blood and organ safety, food and water safety, and infection control.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
